blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3218376

EP3218376 - BROMODOMAIN INHIBITORS AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  30.10.2020
Database last updated on 24.08.2024
FormerThe patent has been granted
Status updated on  22.11.2019
FormerGrant of patent is intended
Status updated on  26.06.2019
FormerExamination is in progress
Status updated on  12.10.2018
FormerRequest for examination was made
Status updated on  18.08.2017
FormerThe international publication has been made
Status updated on  07.06.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080-4990 / US
For all designated states
Constellation Pharmaceuticals, Inc.
215 First Street, Suite 200
Cambridge, MA 02142 / US
[2017/38]
Inventor(s)01 / ALBRECHT, Brian K.
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
02 / BELLON, Steven F.
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
03 / BURDICK, Daniel J.
1 DNA Way
South San Francisco, California 94080-4990 / US
04 / COTE, Alexandre
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
05 / CRAWFORD, Terry
1 DNA Way
South San Francisco, California 94080-4990 / US
06 / DAKIN, Les A.
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
07 / HSIAO-WEI TSUI, Vickie
1 DNA Way
South San Francisco, California 94080-4990 / US
08 / HEWITT, Michael Charles
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
09 / LEBLANC, Yves
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
10 / MAGNUSON, Steven R.
1 DNA Way
South San Francisco, California 94080-4990 / US
11 / NASVESCHUK, Christopher G.
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
12 / ROMERO, F., Anthony
1 DNA Way
South San Francisco, California 94080-4990 / US
13 / TANG, Yong
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
14 / TAYLOR, Alexander M.
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
15 / WANG, Shumei
1 DNA Way
South San Francisco, California 94080-4990 / US
 [2019/52]
Former [2017/38]01 / ALBRECHT, Brian K.
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
02 / BELLON, Steven F.
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
03 / BURDICK, Daniel J.
1 DNA Way
South San Francisco, California 94080-4990 / US
04 / COTE, Alexandre
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
05 / CRAWFORD, Terry
1 DNA Way
South San Francisco, California 94080-4990 / US
06 / DAKIN, Les A.
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
07 / HSIAO-WEI TSUI, Vickie
1 DNA Way
South San Francisco, California 94080-4990 / US
08 / HEWITT, Michael Charles
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
09 / LEBLANC, Yves
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
10 / MAGNUSON, Steven R.
1 DNA Way
South San Francisco, California 94080-4990 / US
11 / NASVESCHUK, Christopher G.
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
12 / ROMERO, F. Anthony
1 DNA Way
South San Francisco, California 94080-4990 / US
13 / TANG, Yong
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
14 / TAYLOR, Alexander M.
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
15 / WANG, Shumei
1 DNA Way
South San Francisco, California 94080-4990 / US
Representative(s)Müller-Boré & Partner Patentanwälte PartG mbB
Friedenheimer Brücke 21
80639 München / DE
[2017/38]
Application number, filing date15801563.610.11.2015
[2017/38]
WO2015US59997
Priority number, dateUS201462077711P10.11.2014         Original published format: US 201462077711 P
[2017/38]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016077375
Date:19.05.2016
Language:EN
[2016/20]
Type: A1 Application with search report 
No.:EP3218376
Date:20.09.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 19.05.2016 takes the place of the publication of the European patent application.
[2017/38]
Type: B1 Patent specification 
No.:EP3218376
Date:25.12.2019
Language:EN
[2019/52]
Search report(s)International search report - published on:EP19.05.2016
ClassificationIPC:C07D471/04, C07D519/00
[2017/38]
CPC:
A61K31/40 (EP,US); C07D471/04 (EP,CN,US); A61P1/00 (EP);
A61P1/04 (EP); A61P1/16 (EP); A61P1/18 (EP);
A61P11/00 (EP); A61P11/06 (EP); A61P13/12 (EP);
A61P17/00 (EP); A61P17/02 (EP); A61P17/04 (EP);
A61P17/06 (EP); A61P19/00 (EP); A61P19/02 (EP);
A61P19/06 (EP); A61P19/08 (EP); A61P21/00 (EP);
A61P25/00 (EP); A61P25/28 (EP); A61P27/02 (EP);
A61P29/00 (EP); A61P3/10 (EP); A61P35/00 (EP);
A61P35/02 (EP); A61P37/02 (EP); A61P37/06 (EP);
A61P43/00 (EP); A61P5/00 (EP); A61P5/16 (EP);
A61P7/04 (EP); A61P9/00 (EP); A61P9/10 (EP);
A61P9/14 (EP); C07D519/00 (EP,CN,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/38]
Extension statesBA01.06.2017
ME01.06.2017
Validation statesMA01.06.2017
MD01.06.2017
TitleGerman:BROMODOMAININHIBITOREN UND DEREN VERWENDUNG[2019/28]
English:BROMODOMAIN INHIBITORS AND USES THEREOF[2017/38]
French:INHIBITEURS DE BROMODOMAINE ET LEURS UTILISATIONS[2019/28]
Former [2017/38]BROMODOMAINHEMMER UND VERWENDUNGEN DAVON
Former [2017/38]INHIBITEURS DE BROMODOMAINES ET LEURS UTILISATIONS
Entry into regional phase01.06.2017National basic fee paid 
01.06.2017Designation fee(s) paid 
01.06.2017Examination fee paid 
Examination procedure31.05.2017Date on which the examining division has become responsible
01.06.2017Examination requested  [2017/38]
12.01.2018Amendment by applicant (claims and/or description)
16.10.2018Despatch of a communication from the examining division (Time limit: M04)
08.02.2019Reply to a communication from the examining division
27.06.2019Communication of intention to grant the patent
30.10.2019Fee for grant paid
30.10.2019Fee for publishing/printing paid
30.10.2019Receipt of the translation of the claim(s)
Opposition(s)28.09.2020No opposition filed within time limit [2020/49]
Fees paidRenewal fee
13.11.2017Renewal fee patent year 03
14.11.2018Renewal fee patent year 04
14.11.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU10.11.2015
AL25.12.2019
AT25.12.2019
CY25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
ES25.12.2019
FI25.12.2019
HR25.12.2019
IT25.12.2019
LT25.12.2019
LV25.12.2019
MC25.12.2019
MK25.12.2019
MT25.12.2019
NL25.12.2019
PL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SI25.12.2019
SK25.12.2019
SM25.12.2019
TR25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
IS25.04.2020
PT20.05.2020
[2022/32]
Former [2022/27]HU10.11.2015
AL25.12.2019
AT25.12.2019
CY25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
ES25.12.2019
FI25.12.2019
HR25.12.2019
IT25.12.2019
LT25.12.2019
LV25.12.2019
MC25.12.2019
MT25.12.2019
NL25.12.2019
PL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SI25.12.2019
SK25.12.2019
SM25.12.2019
TR25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
IS25.04.2020
PT20.05.2020
Former [2021/31]AL25.12.2019
AT25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
ES25.12.2019
FI25.12.2019
HR25.12.2019
IT25.12.2019
LT25.12.2019
LV25.12.2019
MC25.12.2019
NL25.12.2019
PL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SI25.12.2019
SK25.12.2019
SM25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
IS25.04.2020
PT20.05.2020
Former [2021/10]AL25.12.2019
AT25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
ES25.12.2019
FI25.12.2019
HR25.12.2019
IT25.12.2019
LT25.12.2019
LV25.12.2019
NL25.12.2019
PL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SI25.12.2019
SK25.12.2019
SM25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
IS25.04.2020
PT20.05.2020
Former [2020/51]AL25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
ES25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
NL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SI25.12.2019
SK25.12.2019
SM25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
IS25.04.2020
PT20.05.2020
Former [2020/47]AL25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
ES25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
NL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SK25.12.2019
SM25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
IS25.04.2020
PT20.05.2020
Former [2020/40]AL25.12.2019
CZ25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
NL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SK25.12.2019
SM25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
IS25.04.2020
PT20.05.2020
Former [2020/37]AL25.12.2019
CZ25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
NL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SK25.12.2019
SM25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
PT20.05.2020
Former [2020/36]AL25.12.2019
CZ25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
NL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
PT20.05.2020
Former [2020/35]AL25.12.2019
CZ25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
NL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
Former [2020/32]AL25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
NL25.12.2019
RS25.12.2019
SE25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
Former [2020/25]FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
RS25.12.2019
SE25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
Former [2020/23]FI25.12.2019
LT25.12.2019
LV25.12.2019
SE25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
Former [2020/22]FI25.12.2019
LT25.12.2019
SE25.12.2019
BG25.03.2020
NO25.03.2020
Former [2020/21]NO25.03.2020
Cited inInternational search[I]US2014162971  (WANG LE [US], et al) [I] 1-24,26-52 * paragraphs [1416] , [1425]; claim 1 *;
 [A]US2014256710  (LIU DACHUN [US], et al) [A] 1-52 * the whole document *;
 [A]  - DANIEL GALLENKAMP ET AL, "Bromodomains and Their Pharmacological Inhibitors", CHEMMEDCHEM, (20140304), vol. 9, no. 3, doi:10.1002/cmdc.201300434, ISSN 1860-7179, pages 438 - 464, XP055124420 [A] 1-52 * the whole document *

DOI:   http://dx.doi.org/10.1002/cmdc.201300434
 [A]  - JEAN-MARC GARNIER ET AL, "BET bromodomain inhibitors: a patent review", EXPERT OPINION ON THERAPEUTIC PATENTS, (201402), vol. 24, no. 2, doi:10.1517/13543776.2014.859244, ISSN 1354-3776, pages 185 - 199, XP055121821 [A] 1-52 * the whole document *

DOI:   http://dx.doi.org/10.1517/13543776.2014.859244
by applicantUS4943533
 US5212290
 EP0659439
 US5457105
 US5475001
 WO9603397
 WO9630347
 WO9633978
 WO9633980
 WO9640210
 US5616582
 US5654307
 US5679683
 WO9738983
 WO9814451
 US5747498
 US5760041
 US5770599
 US5804396
 WO9843960
 WO9850433
 WO9850038
 US5866572
 WO9906378
 WO9906396
 WO9909016
 US5891996
 WO9924037
 US6002008
 US6084095
 US6140332
 US6235883
 US6265410
 US6344459
 US6344455
 US6391874
 US6399602
 US6455534
 US6521620
 US6596726
 US6602863
 US6713484
    - STRUHL K., GENES DEV., (1989), vol. 12, no. 5, pages 599 - 606
    - JEANMOUGIN F. ET AL., TRENDS BIOCHEM. SCI., (1997), vol. 22, no. 5, pages 151 - 153
    - TAMKUN J.W. ET AL., CELL, (1992), vol. 7, no. 3, pages 561 - 572
    - PRINJHA ET AL., TRENDS PHARM. SCI., (2012), vol. 33, no. 3, pages 146 - 153
    - MULLER ET AL., EXPERT REV., (201109), vol. 13, no. 29, pages 1 - 20
    - "the Periodic Table of the Elements", DAVID R. LIDE, Handbook of Chemistry and Physics, 75th ed., 00001994
    - WILEN ET AL., TETRAHEDRON, (1977), vol. 33, page 2725
    - WILEN, S.H., Tables of Resolving Agents and Optical Resolutions, UNIV. OF NOTRE DAME PRESS, (1972), page 268
    - ANGEW CHEM. INTL. ED. ENGL., (1994), vol. 33, pages 183 - 186
    - STRAGLIOTTO ET AL., EUR. J. CANCER, (1996), vol. 32A, pages 636 - 640
    - JOHNS, J. BIOL. CHEM., (2004), vol. 279, no. 29, pages 30375 - 30384
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.